KPN2 silencing, miR-411-5p overexpression, and AKT inhibitors (e.g., MK2206) can reverse KDM4A-AS1-enhanced hepatoma cell proliferation, migration, and epithelial-mesenchymal transformation. Here, KDM4A is linked to hepatocellular carcinoma.